NHS Patients

0333 202 0300

Medico Legal

0333 202 3188

Self Pay & PMI

0333 200 2064

20 November 2020
Hydroxychloroquine Retinopathy Monitoring Service – go live

We are delighted to announce that the InHealth Intelligence Team have gone live with a new contract to provide a Hydroxychloroquine (HCQ) Retinopathy Monitoring Service for people in Southampton.

Hydroxychloroquine (HCQ) is an anti-malarial/anti-inflamatory drug that can be used in the treatment of a variety of autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis. The risk of retinal toxicity from HCQ has been recognised for many years and it can be irreversible, leading to significant visual impairment and sight loss. However, HCQ is considered a useful drug with fewer side-effects than many of the alternatives.

This service will offer a baseline assessment for people starting on HCQ, and annual screening for those who have been on HCQ for five or more years, and one or more years if they have additional risk factors.

AAA
SCREENING

AUDIOLOGY

BREAST
SCREENING

CARDIAC MRI & CT
CHILD HEALTH INFORMATION
CT
DEXA
DIABETIC EYE SCREENING
ENT
ECHO, ECG & BP
ENDOSCOPY
INTERVENTIONAL CARDIOLOGY
LUNG HEALTH CHECKS
MRI

PATIENT
REFERRAL

PET-CT
REPORTING
ULTRASOUND
UPRIGHT MRI
X-RAY